Literature DB >> 3948300

In vitro comparative studies of the myelotoxicity and antitumor activity of 6-[bis-(2-chloroethyl)-amino]-6-deoxy-D-glucose versus melphalan utilizing the CFU-C and HTSCA assays.

P Lazarus, M Dufour, G Isabel, L C Panasci.   

Abstract

6-[Bis-(2-chloroethyl)-amino]-6-deoxy-D-glucose (C-6) is a new glucose-containing nitrogen mustard that has significant activity for murine P388 leukemia with relative sparing of bone marrow in mice. The in vitro myelotoxicity of C-6 compared with that of melphalan, a clinically active, myelosuppressive nitrogen mustard, was determined in the CFU-C assay in human bone marrow samples obtained from normal volunteers. There was no significant difference between the myelosuppressive actions of C-6 and melphalan at any of the concentrations used except for 4.0 microM, at which C-6 was significantly (P less than 0.05) more toxic than melphalan. Both agents decreased the number of bone marrow cell colonies to approximately 12% of control at 6.6 microM (1 h incubation), which is a good approximation of melphalan's CxT (concentration by time) in man. We used the human tumor stem cell assay (HTSCA) to investigate in vitro antitumor activity. We obtained two specimens of malignant melanoma and two of malignant ovarian carcinoma from patients not previously treated with chemotherapy. The antitumor activity of melphalan was either similar to or greater than that of C-6 at all concentrations utilized against any of the four tumor specimens, except at 1.3 microM for tumor I. In particular, there was no significant difference in the antitumor activities of the two agents at 6.6 microM. These results suggest that C-6 will not be less myelosuppressive than melphalan at doses that produce equivalent antitumor activity in man. In addition, C-6 did not demonstrate increased myelotoxicity for normal human bone marrow cells incubated in glucose-deficient medium as against medium containing 300 mg% glucose at any of the concentrations used. This suggests that C-6 is not transported into normal human bone marrow cells via the glucose transport system, despite the presence of a glucose moiety within the molecule.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3948300     DOI: 10.1007/bf00256165

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  19 in total

1.  Synthesis of chlorozotocin, the 2-chloroethyl analog of the anticancer antibiotic streptozotocin.

Authors:  T P Johnston; G S McCaleb; J A Montgomery
Journal:  J Med Chem       Date:  1975-01       Impact factor: 7.446

2.  Structure-activity studies of methylnitrosourea antitumor agents with reduced murine bone marrow toxicity.

Authors:  L C Panasci; P A Fox; P S Schein
Journal:  Cancer Res       Date:  1977-09       Impact factor: 12.701

3.  A structure-activity analysis of chemical and biological parameters of chloroethylnitrosoureas in mice.

Authors:  L C Panasci; D Green; R Nagourney; P Fox; P S Schein
Journal:  Cancer Res       Date:  1977-08       Impact factor: 12.701

4.  Human bone marrow colony growth in agar-gel.

Authors:  B L Pike; W A Robinson
Journal:  J Cell Physiol       Date:  1970-08       Impact factor: 6.384

5.  Kinetics of intravenous melphalan.

Authors:  D S Alberts; S Y Chang; H S Chen; T E Moon; T L Evans; R L Furner; K Himmelstein; J F Gross
Journal:  Clin Pharmacol Ther       Date:  1979-07       Impact factor: 6.875

6.  Effect of enzymatic disaggregation on proliferation of human tumor cells in soft agar.

Authors:  A W Hamburger; C P White; K Tencer
Journal:  J Natl Cancer Inst       Date:  1982-06       Impact factor: 13.506

7.  Phase I studies on chlorozotocin.

Authors:  D Hoth; P Woolley; D Green; J Macdonald; P Schein
Journal:  Clin Pharmacol Ther       Date:  1978-06       Impact factor: 6.875

8.  Comparison of the transport of chlorozotocin and CCNU in L1210 leukemia and murine bone marrow cells in vitro.

Authors:  P Lazarus; J S Germina; M Dufour; G Palmer; D Wallace; L C Panasci
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

9.  Prospective clinical trial of a human tumor cloning system.

Authors:  D D Von Hoff; G M Clark; B J Stogdill; M F Sarosdy; M T O'Brien; J T Casper; D E Mattox; C P Page; A B Cruz; J F Sandbach
Journal:  Cancer Res       Date:  1983-04       Impact factor: 12.701

10.  Pharmacology of chlorozotocin Nsc-178248), a new nitrosourea antitumor agent.

Authors:  P S Schein; L Panasci; P V Woolley; T Anderson
Journal:  Cancer Treat Rep       Date:  1976-06
View more
  2 in total

1.  D-19575--a sugar-linked isophosphoramide mustard derivative exploiting transmembrane glucose transport.

Authors:  J Pohl; B Bertram; P Hilgard; M R Nowrousian; J Stüben; M Wiessler
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

2.  SPHK1 regulates proliferation and survival responses in triple-negative breast cancer.

Authors:  Arpita Datta; Ser Yue Loo; Baohua Huang; Lingkai Wong; Sheryl S L Tan; Tuan Zea Tan; Soo-Chin Lee; Jean Paul Thiery; Yaw Chyn Lim; Wei Peng Yong; Yulin Lam; Alan Prem Kumar; Celestial T Yap
Journal:  Oncotarget       Date:  2014-08-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.